
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
EDIT | NASDAQ | USD | Real-time | |
0IFK | London | USD | Real-time | |
8EM | TradeGate | EUR | Delayed |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
David T. Scadden | 72 | 2019 | Independent Director |
Elliott M. Levy | 67 | 2023 | Independent Director |
Gilmore O’Neill | 61 | 2022 | President, CEO & Director |
Jessica Hopfield | 60 | 2018 | Independent Chairman |
Andrew J. Hirsch | 54 | 2017 | Independent Director |
Bernadette Mary Connaughton | 67 | 2021 | Independent Director |
George McDonald Church | 71 | 2013 | Co-Founder & Scientific Advisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review